Our data indicate that selective FGFR inhibitor BGJ398 is effective against IM-resistant GIST T-1R cells with the RTK switch (c-KIT/FGFR2α) Of note, crizotinib (CR) and cabozantinib (CB) as potent c-MET-inhibitors also reduced the viability of IM-resistant GISTs, which is consistent with c-MET overexpression observed in this GIST subline. This evidence concerns the gene MET and gastrointestinal stromal tumor.